SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin gains as its arm launches Generic Trizivir Tablets

18 Dec 2013 Evaluate

Lupin is currently trading at Rs. 892.30, up by 11.90 points or 1.35% from its previous closing of Rs. 880.90 on the BSE.

The scrip opened at Rs. 890.00 and has touched a high and low of Rs. 898.55 and Rs. 881.50 respectively. So far 86,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 946.35 on 11-Oct-2013 and a 52 week low of Rs. 569.00 on 01-Mar-2013.

Last one week high and low of the scrip stood at Rs. 888.60 and Rs. 864.00 respectively. The current market cap of the company is Rs. 39,990 crore.

The promoters holding in the company stood at 46.78% while Institutions and Non-Institutions held 43.52% and 9.69% respectively. Pharma Major Lupin’s  US subsidiary-Lupin Pharmaceuticals Inc. has launched  Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300mg (base) / 150mg / 300mg in the US after the US District Court for the District of Delaware ruled that the Lupin’s generic version of Trizivir did not infringe on patents. Lupin had earlier received approval for the same.

Lupin’s Abacavir Sulfate, Lamivudine Zidovudine 300mg (Base)/150mg/300mg Tablets are the AB?rated generic equivalent of ViiV Healthcare’s (ViiV) Trizivir Tablets, 300mg (base) / 150mg / 300mg and are indicated in combination with other antiretrovirals or alone for the treatment of HIV?1 infection. Lupin is the first applicant to file an ANDA for Trizivir Tablets and as such is entitled to 180 days of marketing exclusivity.

Trizivir Tablets, 300mg (base) / 150mg / 300mg had annual U.S sales of approximately $ 111.6 million (IMS MAT Sep, 2013).

Lupin Share Price

2324.25 -2.25 (-0.10%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×